Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine

Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine

The continuous evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants poses a challenge to determine the optimal updated composition of the coronavirus disease 2019 (COVID-19) vaccine. The present study aimed to investigate the immunogenicity of the Delta monovalent vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: Wanting Li, Tiantian Zhao, Bai Tao, Liwei Zhao, Hang Xiao, Xinyu Ding, Chuang Li, Lin Chen, Hao Cheng, Yang Lou, Yuxin Chen, Chao Wu
Formato: Artículo
Lenguaje:English
Publicado: Taylor & Francis Group 2023-08-01
Colección:Human Vaccines & Immunotherapeutics
Materias:
sars-cov-2
omicron
bivalent vaccine
immunogenicity
monoclonal antibody
Acceso en línea:http://dx.doi.org/10.1080/21645515.2023.2264589

Internet

http://dx.doi.org/10.1080/21645515.2023.2264589

Ejemplares similares